Hedge Fund to Biotech

Martin Shkreli describes building a biotech company by identifying undervalued pharmaceutical assets through extensive research and development. His approach leverages financial analysis skills from hedge fund experience to find and develop promising drug candidates.

Key Points:

• Asset Discovery Process:

  • Use PubMed database (36 million biomedical research papers)
  • Study pharmaceutical compounds that major companies abandoned
  • Look for drugs that could be repurposed for different diseases
  • Research multiple potential applications for each drug

• First Success Example:

  • Bought drug license from Bristol Myers for $2 million
  • Drug was originally for hypertension but pivoted to rare kidney disease
  • Took 10 years to get FDA approval
  • Company value grew to $1.5 billion
  • Started with research/development phase rather than marketed drugs

• Development Strategy:

  • Focus on rare diseases with unmet medical needs
  • Conduct clinical trials to prove efficacy
  • Take company public to raise development funds
  • Build value through clinical evidence and FDA approval process

• Business Model Benefits:

  • Lower initial capital requirements compared to marketing existing drugs
  • Higher potential returns if drug succeeds
  • Value creation through development process rather than price increases
  • Multiple potential applications provide backup opportunities

• Key Success Factors:

  • Deep understanding of pharmaceutical industry
  • Ability to identify undervalued assets
  • Patience for long development timeline
  • Access to capital markets for funding